This Policy Shift Is Big News for Gilead Sciences (GILD)

March 17, 2015 4:26 PM

12 0

By and large, Gilead Sciences had a banner year in 2014. In December 2013 Gilead witnessed its revolutionary oral hepatitis C therapy Sovaldi be approved by the Food and Drug Administration, then in October 2014 it observed Harvoni for HCV also being approved.

A major step forward in hepatitis C patient care Both drugs represent major leaps forward in HCV therapy compared to previous standards of care.

Read more

To category page